Clinical Trial Update: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on an IL-15 super agonist ALT-803 for relapse of hematologic malignancies after allogeneic stem cell transplant, completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes

Drugs mentioned

• ALT-803 (Interleukin-15 super-agonist)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-08-12